ArticleBritish journal of haematology2020
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
Article in British journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2022Guideline
- The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review.Technology in cancer research & treatmentPooled it
- Association between CAR T-cell persistence and improved response to salvage radiotherapy in patients with DLBCL.Acta oncologica (Stockholm, Sweden) · 2026Article
- A new perspective on radiotherapy in the comprehensive treatment of cancer.Precision radiation oncology · 2026Review
- Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: A COVID-era ILROG collaborative report.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025Article
- Combining CAR-T therapy with radiotherapy or not in refractory/relapsed diffuse large B-cell lymphoma: A comparative study.Clinical and translational radiation oncology · 2025Article
- CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy.Hematological oncology · 2025Article
- [Radiotherapy of non-Hodgkin lymphoma-discussion of modern treatment concepts and innovations].Radiologie (Heidelberg, Germany) · 2025Review
- Role of Radiation in Combination With CD30-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma.Advances in radiation oncology · 2024Article
- Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era.BMC cancer · 2024Article
- Management of aggressive lymphoma after CAR T-cell therapy failure.Hematology. American Society of Hematology. Education Program · 2023Review
- The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors.Biomarker research · 2023Review
- Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy.Haematologica · 2023Article
- Application of interim PET-CT in first-line treatment decision-making for lymphoma.Journal of Zhejiang University. Science. B · 2023Review
- The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.Experimental hematology & oncology · 2023Review
- Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy.Blood advances · 2023Article
- Review
- Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.Clinical and translational radiation oncology · 2023Article
- Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.Frontiers in pediatrics · 2023Review
- Radiation for hematologic malignancies: from cell killing to immune cell priming.Frontiers in oncology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.